Induction treatment with bortezomib-cyclophosphamide-dexamethasone (CyBorD) for newly diagnosed transplant-eligible patients with multiple myeloma
-
- TSUKADA Nobuhiro
- Division of Hematology, Japanese Red Cross Medical Center
-
- IKEDA Masahiro
- Division of Hematology, Japanese Red Cross Medical Center
-
- SHINGAKI Sumito
- Division of Hematology, Japanese Red Cross Medical Center
-
- MIYAZAKI Kanji
- Division of Hematology, Japanese Red Cross Medical Center
-
- MESHITSUKA Sohsuke
- Division of Hematology, Japanese Red Cross Medical Center
-
- YOSHIKI Yumiko
- Division of Hematology, Japanese Red Cross Medical Center
-
- ABE Yu
- Division of Hematology, Japanese Red Cross Medical Center
-
- SUZUKI Kenshi
- Division of Hematology, Japanese Red Cross Medical Center
Bibliographic Information
- Other Title
-
- 移植適応未治療多発性骨髄腫に対するCyBorD療法の検討
- 臨床研究 移植適応未治療多発性骨髄腫に対するCyBorD療法の検討
- リンショウ ケンキュウ イショク テキオウ ミチリョウ タハツセイ コツズイシュ ニ タイスル CyBorD リョウホウ ノ ケントウ
Search this article
Abstract
Twenty-nine transplant eligible newly diagnosed multiple myeloma (NDMM) patients have received Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) as induction treatment in our institute since November 2011. CyBorD is composed of CPA 300 mg/m2 p.o., Bor 1.3 mg/m2 i.v. or s.c., and Dex 40 mg/body p.o. on days 1, 8, 15, and 22. The median number of CyBorD cycles was 4 (range 2-6), except in one patient who progressed during the first cycle. Grade 4 neutropenia was observed in 2 patients, but none experienced grade 2 thrombocytopenia. Grade 3 non-hematologic adverse events were observed in two patients with varicella-zoster virus reactivation. Responses after CyBorD were ≥PR in 72%, ≥VGPR in 52%, ≥CR in 21%, and sCR in 21%. Autologous stem cells were harvested in 27 patients. Seventeen of these 27 patients received high-dose melphalan and autologous stem cell transplantation (ASCT) within 12 months after diagnosis. Patients with ≥CR increased to 59% after ASCT. Our data suggest the efficacy and the feasibility of administering CyBorD to transplant eligible NDMM patients.
Journal
-
- Rinsho Ketsueki
-
Rinsho Ketsueki 56 (8), 1069-1075, 2015
The Japanese Society of Hematology
- Tweet
Details 詳細情報について
-
- CRID
- 1390001205034965376
-
- NII Article ID
- 130005096273
-
- NII Book ID
- AN00252940
-
- ISSN
- 18820824
- 04851439
-
- NDL BIB ID
- 026704295
-
- PubMed
- 26345569
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed